The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis.
Event: ESC Congress 2021 - The Digital Experience
Topic: Cardiac Hypertrophy
Session: Congress committee e-posters choice in basic science
Empagliflozin improves left ventricular diastolic function in db/db mice without altering cardiac expression of enzymes relevant for ketone body or branched chain amino acid catabolism.
Event: ESC Congress 2018
Topic: Pharmacotherapy
Session: Targeting reverse remodelling in heart failure
